Digoxigenin-end labeled oligonucleotides facilitate the detection of minimal residual disease in acute lymphoblastic leukemia.
Nakao
M
M
Janssen
J W
JW
Schäfer
M
M
Bartram
C R
CR
D000328:Adult; D001345:Autoradiography; D004273:DNA, Neoplasm / Q000032:analysis*; D004076:Digoxigenin; D004797:Enzyme-Linked Immunosorbent Assay; D015328:Gene Rearrangement, B-Lymphocyte, Light Chain; D016694:Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; D005803:Genes, Immunoglobulin; D006801:Humans; D008163:Luminescent Measurements; D009363:Neoplasm Proteins / Q000235:genetics; D018365:Neoplasm, Residual; D009693:Nucleic Acid Hybridization; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000473:pathology*; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity
D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D011933:Reagent Kits, Diagnostic; D004076:Digoxigenin